Publications / News
Publications
Vaishampayan UN*, Thakur A*, Chen W, Deol A, Patel M, Dobson K, Dickow B, Schalk D, Schienschang A, Whitaker S, Polend A, Fontana JA, Heath EI, Lum LG. Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2023 Jan 4;29(1):122-133. doi: 10.1158/1078-0432.CCR-22-1601. PMID: 36255393;(*Shared Authorship) https://pubmed.ncbi.nlm.nih.gov/36255393/
Kubicka E, Lum LG, Huang M, Thakur A#. Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia. Front Immunol. 2022 Nov 1;13:899468. doi: 10.3389/fimmu.2022.899468. PMID: 36389764; PMCID: PMC9663847. (#Corresponding Author) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663847/
Qiao, G., Kone, L. B., Phillips, E. H., Lee, S. S., Brown, G. E., Khetani, S. R., Thakur, A., Lum, L. G., Prabhakar, B. S., and Maker, A. V. (2022) LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer. Oncogene 41, 2054-2068 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975745/
Sturek, J. M., Thomas, T. A., Gorham, J. D., Sheppard, C. A., Raymond, A. H., Petros De Guex, K., Harrington, W. B., Barros, A. J., Madden, G. R., Alkabab, Y. M., Lu, D. Y., Liu, Q., Poulter, M. D., Mathers, A. J., Thakur, A., Schalk, D. L., Kubicka, E. M., Lum, L. G., and Heysell, S. K. (2022) Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile. Microbiol Spectr 10, e025602